T. Rowe Price Associates’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $66.3M | Sell |
|
|||||
|
2025
Q2 | $92.1M | Buy |
|
|||||
|
2025
Q1 | $59.4M | Buy |
|
|||||
|
2024
Q4 | $62.3M | Buy |
|
|||||
|
2024
Q3 | $83.6M | Buy |
|
|||||
|
2024
Q2 | $52.4M | Buy |
|
|||||
|
2024
Q1 | $32.7M | Sell |
|
|||||
|
2023
Q4 | $55.2M | Sell |
|
|||||
|
2023
Q3 | $59.7M | Sell |
|
|||||
|
2023
Q2 | $102M | Sell |
|
|||||
|
2023
Q1 | $81.5M | Sell |
|
|||||
|
2022
Q4 | $101M | Buy |
|
|||||
|
2022
Q3 | $107M | Sell |
|
|||||
|
2022
Q2 | $136M | Sell |
|
|||||
|
2022
Q1 | $158M | Buy |
|
|||||
|
2021
Q4 | $207M | Sell |
|
|||||
|
2021
Q3 | $240M | Sell |
|
|||||
|
2021
Q2 | $385M | Sell |
|
|||||
|
2021
Q1 | $346M | Sell |
|
|||||
|
2020
Q4 | $541M | Buy |
|
|||||
|
2020
Q3 | $156M | Buy |
|
|||||
|
2020
Q2 | $63.4M | Buy |
|
|||||
|
2020
Q1 | $21.2M | Buy |
|
|||||
|
2019
Q4 | $7.27M | Sell |
|
|||||
|
2019
Q3 | $6.74M | Sell |
|
|||||
|
2019
Q2 | $9.99M | Sell |
|
|||||
|
2019
Q1 | $11.2M | Buy |
|
|||||
|
2018
Q4 | $9.86M | Buy |
|
|||||
|
2018
Q3 | $10.3M | Buy |
|
|||||
|
2018
Q2 | $5.55M | Sell |
|
|||||
|
2018
Q1 | $7.32M | Buy |
|